PHIO - National Spotlight Features Phio's Innovative RNAi Technology Platform | Benzinga
—Program will be airing on PBS with Dennis Quaid in April
—It will also be seen on Fox Business Network
MARLBOROUGH, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced its INTASYL platform will be the focus of Viewpoint, a national program hosted by Dennis Quaid. The program will air in April on PBS stations across the country.
The spotlight will also be featured nationally on Fox Business Network on April 24th, and regionally on a number of networks, including CNN and MSNBC, throughout the month of April.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that ...